Get the Stockscreener App
0.8946
0.43%
-0.0039
After Hours:
.91
0.0154
+1.72%
Immunic Inc stock is traded at $0.8946, with a volume of 1.27M.
It is down -0.43% in the last 24 hours and up +12.63% over the past month.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
See More
Previous Close:
$0.8985
Open:
$0.8986
24h Volume:
1.27M
Relative Volume:
0.98
Market Cap:
$88.25M
Revenue:
-
Net Income/Loss:
$-93.61M
P/E Ratio:
-0.424
EPS:
-2.11
Net Cash Flow:
$-71.16M
1W Performance:
-4.83%
1M Performance:
+12.63%
6M Performance:
-0.62%
1Y Performance:
-36.10%
1-Day Range:
$0.88
$0.9098
1-Week Range:
$0.8606
$0.977
52-Week Range:
$0.561
$1.73
Immunic Inc Stock (IMUX) Company Profile
Name
Immunic Inc
Sector
Industry
Phone
(332) 255-9818
Address
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
0.8946 | 88.64M | 0 | -93.61M | -71.16M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-29-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-25-25 | Initiated | William Blair | Outperform |
| Nov-25-24 | Initiated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-27-24 | Initiated | B. Riley Securities | Buy |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Apr-15-21 | Initiated | Aegis Capital | Buy |
| Mar-24-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Aug-07-20 | Resumed | ROTH Capital | Buy |
| Jul-20-20 | Initiated | BMO Capital Markets | Outperform |
| Jun-05-20 | Initiated | Wedbush | Outperform |
| May-11-20 | Initiated | H.C. Wainwright | Buy |
| Mar-25-20 | Initiated | ROTH Capital | Buy |
| Jul-11-19 | Initiated | Chardan Capital Markets | Buy |
View All
Immunic Inc Stock (IMUX) Latest News
Will Immunic Inc. stock see PE expansionWeekly Trend Report & Capital Efficiency Focused Strategies - newser.com
Why Immunic Inc. stock could outperform in 2025Stop Loss & Daily Entry Point Trade Alerts - newser.com
Detecting price anomalies in Immunic Inc. with AIJuly 2025 Institutional & Expert Approved Trade Ideas - newser.com
Price momentum metrics for Immunic Inc. explained2025 Price Targets & Free Verified High Yield Trade Plans - newser.com
Immunic targeting mental and physical challenges facing MS patientsICYMI - Proactive financial news
Can Immunic Inc. recover in the next quarterEarnings Trend Report & Weekly High Conviction Ideas - newser.com
Immunic marks World Mental Health Day, highlighting the mental consequence for MS patients - Proactive financial news
Why Immunic Inc. (10VA) stock fits value portfolios2025 Support & Resistance & Long-Term Growth Stock Strategies - newser.com
Why Immunic Inc. (10VA) stock benefits from AI revolutionProduct Launch & Verified Momentum Stock Alerts - newser.com
Comparing Immunic Inc. in custom built stock radarsJuly 2025 News Drivers & Technical Analysis for Trade Confirmation - newser.com
Immunic (NASDAQ:IMUX) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat
Immunic Presents Promising Phase 2 Trial Results - MSN
Immunic receives notice of allowance for vidofludimus calcium patent - MSN
Applying chart zones and confluence areas to Immunic Inc.Market Performance Report & Free Fast Entry Momentum Trade Alerts - newser.com
Is Immunic Inc. (10VA) stock positioned for secular growthQuarterly Portfolio Report & Daily Volume Surge Signals - newser.com
Chart overlay techniques for tracking Immunic Inc.Profit Target & Risk Controlled Stock Alerts - newser.com
Risk adjusted return profile for Immunic Inc. analyzed2025 Pullback Review & Expert Curated Trade Ideas - newser.com
Using data tools to time your Immunic Inc. exitEarnings Recap Report & Fast Gain Stock Trading Tips - newser.com
Why Immunic Inc. stock is favored by top institutionsPortfolio Value Summary & Long-Term Growth Plans - newser.com
Using data models to predict Immunic Inc. stock movementGold Moves & Growth Focused Stock Pick Reports - newser.com
Is Immunic Inc. stock ready for a breakout2025 Major Catalysts & Weekly Sector Rotation Insights - newser.com
How to read the order book for Immunic Inc.Earnings Overview Summary & Weekly Sector Rotation Insights - newser.com
Can Immunic Inc. stock sustain institutional interestGDP Growth & Weekly Top Gainers Trade List - newser.com
Can momentum traders help lift Immunic Inc.Earnings Growth Report & Weekly Breakout Stock Alerts - newser.com
Positive Signs As Multiple Insiders Buy Immunic Stock - Yahoo Finance
Chardan Capital Estimates Immunic FY2026 Earnings - MarketBeat
What earnings revisions data tells us about Immunic Inc.Weekly Trend Summary & Comprehensive Market Scan Insights - newser.com
Immunic to Participate in Scientific and Investor Conferences in October - The Malaysian Reserve
Immunic Inc Stock (IMUX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunic Inc Stock (IMUX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tardio Jason | President and COO |
Jun 05 '25 |
Buy |
0.79 |
12,512 |
9,884 |
12,512 |
| Vitt Daniel | CEO and Director |
Jun 04 '25 |
Buy |
0.77 |
15,000 |
11,550 |
29,000 |
| Neermann Joerg | Director |
Jun 04 '25 |
Buy |
0.77 |
70,000 |
53,900 |
170,000 |
| Neermann Joerg | Director |
Jun 05 '25 |
Buy |
0.76 |
30,000 |
22,800 |
200,000 |
| Whaley Glenn | Chief Financial Officer |
Jun 03 '25 |
Buy |
0.71 |
45,000 |
32,076 |
95,510 |
| Rudick Richard Alan | Director |
Jun 03 '25 |
Buy |
0.70 |
143,075 |
100,024 |
230,375 |
| Rudick Richard Alan | Director |
Nov 12 '24 |
Buy |
1.15 |
87,300 |
100,369 |
87,300 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):